HUP0203521A2 - 4-carboxyamino-2-ethyl-1,2,3,4-tetrahydroquinoline crystal as cept inhibitor, process for its preparation, pharmaceutical composition containing the same and its use - Google Patents

4-carboxyamino-2-ethyl-1,2,3,4-tetrahydroquinoline crystal as cept inhibitor, process for its preparation, pharmaceutical composition containing the same and its use

Info

Publication number
HUP0203521A2
HUP0203521A2 HU0203521A HUP0203521A HUP0203521A2 HU P0203521 A2 HUP0203521 A2 HU P0203521A2 HU 0203521 A HU0203521 A HU 0203521A HU P0203521 A HUP0203521 A HU P0203521A HU P0203521 A2 HUP0203521 A2 HU P0203521A2
Authority
HU
Hungary
Prior art keywords
carboxyamino
tetrahydroquinoline
ethyl
crystal
preparation
Prior art date
Application number
HU0203521A
Other languages
Hungarian (hu)
Inventor
Douglas John Meldrum Allen
Troy Anthony Appleton
Lyle Robinson Brostrom
Derek Lawrence Tickner
Original Assignee
Pfizer Products Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Products Inc. filed Critical Pfizer Products Inc.
Publication of HUP0203521A2 publication Critical patent/HUP0203521A2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C07D215/42—Nitrogen atoms attached in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Cephalosporin Compounds (AREA)
  • Quinoline Compounds (AREA)

Abstract

A jelen találmány tárgyát a (I) képletű CETP inhibitorok kristályosformái, a kristályformák előállítására szolgáló eljárások, azinhibitorokat tartalmazó gyógyszerkészítmények, továbbá az inhibitorokalkalmazási eljárásai képezik. ÓThe subject of the present invention is the crystalline forms of the CETP inhibitors of the formula (I), the methods for producing the crystalline forms, the pharmaceutical preparations containing the inhibitors, and the methods of application of the inhibitors. HE

HU0203521A 1999-11-30 2000-11-14 4-carboxyamino-2-ethyl-1,2,3,4-tetrahydroquinoline crystal as cept inhibitor, process for its preparation, pharmaceutical composition containing the same and its use HUP0203521A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US16805199P 1999-11-30 1999-11-30
PCT/IB2000/001650 WO2001040190A1 (en) 1999-11-30 2000-11-14 4-carboxyamino-2-ethyl-1,2,3,4-tetrahydroquinoline crystal as cetp inhibitor

Publications (1)

Publication Number Publication Date
HUP0203521A2 true HUP0203521A2 (en) 2003-02-28

Family

ID=22609901

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0203521A HUP0203521A2 (en) 1999-11-30 2000-11-14 4-carboxyamino-2-ethyl-1,2,3,4-tetrahydroquinoline crystal as cept inhibitor, process for its preparation, pharmaceutical composition containing the same and its use

Country Status (28)

Country Link
EP (1) EP1246804A1 (en)
JP (1) JP2003515592A (en)
KR (1) KR20020058057A (en)
CN (1) CN1402711A (en)
AP (1) AP2002002531A0 (en)
AU (1) AU1048801A (en)
BG (1) BG106854A (en)
BR (1) BR0015836A (en)
CA (1) CA2392979A1 (en)
CO (1) CO5271716A1 (en)
EA (1) EA200200510A1 (en)
EC (1) ECSP003792A (en)
EE (1) EE200200277A (en)
GT (1) GT200000199A (en)
HU (1) HUP0203521A2 (en)
IL (1) IL149097A0 (en)
IS (1) IS6338A (en)
MA (1) MA26845A1 (en)
MX (1) MXPA02005354A (en)
NO (1) NO20022558L (en)
OA (1) OA12099A (en)
PA (1) PA8506301A1 (en)
PE (1) PE20010904A1 (en)
PL (1) PL355892A1 (en)
TN (1) TNSN00231A1 (en)
TR (1) TR200201446T2 (en)
UY (1) UY26454A1 (en)
WO (1) WO2001040190A1 (en)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7115279B2 (en) 2000-08-03 2006-10-03 Curatolo William J Pharmaceutical compositions of cholesteryl ester transfer protein inhibitors
CZ20033341A3 (en) * 2001-06-21 2004-10-13 Pfizeráproductsáinc Self-emulsifying formulations of cholesteryl ester transfer protein inhibitors
GT200200170A (en) 2001-09-28 2003-05-23 PREPARATION OF INHIBITOR OF CETP ANHIDRO
MXPA04007438A (en) 2002-02-01 2004-10-11 Pfizer Prod Inc Pharmaceutical compositions of amorphous dispersions of drugs and lipophilic microphase-forming materials.
EP1920766B1 (en) * 2002-02-01 2017-08-23 Bend Research, Inc Pharmaceutical compositions of amorphous dispersions of drugs and lipophilic microphase-forming materials
EP1469833B1 (en) * 2002-02-01 2021-05-19 Bend Research, Inc. Method for making homogeneous spray-dried solid amorphous drug dispersions utilizing modified spray-drying apparatus
PT1533292E (en) 2002-08-30 2007-05-31 Japan Tobacco Inc Dibenzylamine compound and medicinal use thereof
JP2006508077A (en) 2002-10-04 2006-03-09 ミレニアム・ファーマシューティカルズ・インコーポレイテッド PGD2 receptor antagonist for the treatment of inflammatory diseases
US7504508B2 (en) 2002-10-04 2009-03-17 Millennium Pharmaceuticals, Inc. PGD2 receptor antagonists for the treatment of inflammatory diseases
MXPA05005813A (en) 2002-12-20 2005-12-12 Pfizer Prod Inc Dosage forms comprising a cetp inhibitor and an hmg-coa reductase inhibitor.
US20040132771A1 (en) * 2002-12-20 2004-07-08 Pfizer Inc Compositions of choleseteryl ester transfer protein inhibitors and HMG-CoA reductase inhibitors
EP1622872A1 (en) * 2003-03-28 2006-02-08 Pfizer Products Inc. 1,2,4-substituerte 1,2,3,4-tetrahydro-and 1,2 dihydro-quinoline and 1,2,3,4-tetrahydro-quinoxaline derivatives as cetp inhibitors for the treatment of atherosclerosis and obesity
EP1653927B1 (en) 2003-08-04 2012-01-11 Bend Research, Inc. Pharmaceutical compositions of adsorbates of amorphous drugs and lipophilic microphase-forming materials
CN1863778A (en) 2003-10-08 2006-11-15 伊莱利利公司 Compounds and methods for treating dyslipidemia
CA2562082C (en) * 2004-04-13 2013-06-25 Merck & Co., Inc. Cetp inhibitors for the treatment and prevention of atherosclerosis
JP2008504266A (en) * 2004-06-24 2008-02-14 イーライ リリー アンド カンパニー Compounds and methods for treating dyslipidemia
WO2006033004A1 (en) * 2004-09-23 2006-03-30 Pfizer Products Inc. Quinoline compounds as cetp inhibitors
WO2006033001A1 (en) * 2004-09-23 2006-03-30 Pfizer Products Inc. Quinoline compounds
RU2007135224A (en) 2005-02-24 2009-03-27 Милленниум Фармасьютикалз, Инк. (Us) PGD2 RECEPTOR ANTAGONISTS FOR TREATMENT OF INFLAMMATORY DISEASES
WO2006098394A1 (en) * 2005-03-14 2006-09-21 Japan Tobacco Inc. Method for inhibiting lipid absorption and lipid absorption inhibitor
US7737155B2 (en) 2005-05-17 2010-06-15 Schering Corporation Nitrogen-containing heterocyclic compounds and methods of use thereof
TW200901959A (en) 2007-03-09 2009-01-16 Indigene Pharmaceuticals Inc Combination of metformin R-(+) lipoate and antihyperlipidemic agents for the treatment of diabetic hyperglycemia and diabetic complications
WO2010075068A1 (en) 2008-12-16 2010-07-01 Schering Corporation Pyridopyrimidine derivatives and methods of use thereof
US20110243940A1 (en) 2008-12-16 2011-10-06 Schering Corporation Bicyclic pyranone derivatives and methods of use thereof
AR077208A1 (en) 2009-06-30 2011-08-10 Lilly Co Eli ACID DERIVATIVES TRANS-4 - [[(5S) -5 - [[[3,5-BIS (TRIFLUOROMETIL) PHENYLE] METHYL] (2-METHYL-2H-TETRAZOL-5-IL) AMINO) -2,3, 4,5-TETRAHIDRO-7,9-DIMETIL-1H-1-BENZAZEPIN-1-IL) METHYL) -CYCLHEXANCARBOXYL AND ITS CRYSTALLINE FORMS, PHARMACEUTICAL COMPOSITIONS THAT UNDERSTAND IT, ITS USE TO PREPARE A MEDICAM
KR102456013B1 (en) 2014-07-30 2022-10-18 에프. 호프만-라 로슈 아게 Genetic markers for predicting responsiveness to therapy with hdl-raising or hdl mimicking agent

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5231102A (en) * 1989-03-08 1993-07-27 Merck Sharp & Dohme, Ltd. Tetrahydroquinoline derivatives useful for neurodegenerative disorders
WO1998033775A1 (en) * 1997-02-03 1998-08-06 American Home Products Corporation 2-substituted-1-acyl-1,2-dihydroquinoline derivatives to increase hdl-cholesterol level
US6197786B1 (en) * 1998-09-17 2001-03-06 Pfizer Inc 4-Carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines

Also Published As

Publication number Publication date
PL355892A1 (en) 2004-05-31
BG106854A (en) 2002-12-29
EA200200510A1 (en) 2002-10-31
WO2001040190A1 (en) 2001-06-07
TR200201446T2 (en) 2002-11-21
EP1246804A1 (en) 2002-10-09
NO20022558D0 (en) 2002-05-29
IS6338A (en) 2002-04-12
AU1048801A (en) 2001-06-12
JP2003515592A (en) 2003-05-07
UY26454A1 (en) 2001-07-31
CN1402711A (en) 2003-03-12
ECSP003792A (en) 2002-04-23
KR20020058057A (en) 2002-07-12
IL149097A0 (en) 2002-11-10
PA8506301A1 (en) 2002-08-26
GT200000199A (en) 2002-05-23
AP2002002531A0 (en) 2002-06-30
CO5271716A1 (en) 2003-04-30
CA2392979A1 (en) 2001-06-07
MA26845A1 (en) 2004-12-20
MXPA02005354A (en) 2002-12-11
TNSN00231A1 (en) 2002-05-30
OA12099A (en) 2006-05-04
PE20010904A1 (en) 2001-09-10
NO20022558L (en) 2002-05-29
BR0015836A (en) 2002-08-06
EE200200277A (en) 2003-10-15

Similar Documents

Publication Publication Date Title
HUP0203521A2 (en) 4-carboxyamino-2-ethyl-1,2,3,4-tetrahydroquinoline crystal as cept inhibitor, process for its preparation, pharmaceutical composition containing the same and its use
HUP0303084A2 (en) 17 beta-carbothioate 17-alpha-arylcarbonyloxyloxy androstane derivative as anti-inflammatory agents, process for their preparation and pharmaceutical compositions containing them
HUP0002987A2 (en) Dicyclohexyl-amine salt of cefdinir and process for the preparation of the salt and subsequent liberation of the free compound
HUP0302519A2 (en) Crystalline forms of atorvastatin, process for their preparation and pharmaceutical compositions containing them
HUP0102813A2 (en) New betha crystalline form of perindopril tert-butylamine salt, process for its preparation and pharmaceutical compositions containing it
IL150482A0 (en) Heteroaromatic carboxamide derivatives and their use as inhibitors of the enzyme ikk-2
ATE240316T1 (en) HETEROAROMATIC AMIDES AS INHIBITORS OF FACTOR XA
PT915898E (en) CLARITROMYCIN CRYSTALLINE I FORM
MXPA02011425A (en) Substituted pyrrolopyridinone derivatives useful as phosphodiesterase inhibitors.
HUP0302475A2 (en) A method for treating allergies using substituted pyrazoles
MY106202A (en) Saccharin derivatives useful as proteolytic enzyme inhibitors and preparation thereof.
HUP0301076A2 (en) Linezolid-crystal form ii and preparation thereof
HUP0303034A2 (en) Novel 7-azaindole-derivatives, use thereof as phosphodiesterase 4 inhibitors and method for producing the same
IL149586A0 (en) Pyrimidine derivatives as selective inhibitors of cox-2
HUP0302479A2 (en) Nf-kappa b inhibitor pharmaceutical composition containing substituted benzoic acid derivative as active ingredient
AU2364000A (en) Heterocyclic amides as inhibitors of factor xa
HUP0105308A2 (en) Eletriptan hydrobromide monohydrate, process for its preparation and pharmaceutical compositions containing the same
HUP0402602A2 (en) Method for preparing echinocandin derivatives, their use, pharmaceutical compositions comprising thereof and their intermediates
AU2003271811A8 (en) Novel derivatives of 4,4'-dithiobis-(3-aminobutane-1-sulphonates) and compositions containing same
NO20010559D0 (en) Process for the synthesis of (1H) -benzo [c] quinolizin-3-ones derivatives
HUP0401234A2 (en) A stable pharmaceutical composition of pravastatin and process for its preparation
HUP0303760A2 (en) Substituted benzoic acid derivatives exhibiting nf-kb inhibiting activity and pharmaceutical compositions containing them
HUP0102447A2 (en) Novel octahydro-6,10-dioxo-6h-pyridazino/1,2a//1,2/diazepin-1-carboxylic acid derivatives, preparation method and use for preparing therapeutically active compounds
DE60019157D1 (en) METHOD OF PREPARING ARYLETHANOLAMINE DERIVATIVES FOR THE TREATMENT OF DIABETES AND FATIBILITY
HUP0203270A2 (en) Hydroxamic acid derivative as inhibitor of the formation of human cd23, process for its preparation and pharmaceutical compositions containing the same